Project Number 5R01AG015408-09 Agency/Funding Organization NIA Funding Year 2008 View Full Project Details for AMYLOID BETA PEPTIDE AND APOLIPOPROTEIN E Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category A. Molecular Pathogenesis and Physiology of Alzheimer's Disease and Alzheimer's Disease-related Dementias (AD/ADRDs) 4. ApoE and Lipid Neurobiology a. ApoE in Abeta-Mediated AD Pathogenesis Researcher and Organization Principal Investigator WISNIEWSKI, THOMAS M Principal Investigator First Name THOMAS M Principal Investigator Last Name WISNIEWSKI Awardee Organization NEW YORK UNIVERSITY SCHOOL OF MEDICINE Awardee State New York, N.Y. Contact PI Country United States Project Detail FY Overall Cost $289,734 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official PETANCESKA, SUZANA Related Resources Repository [AlzPED] Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. [AlzPED] Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. [AlzPED] A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. [AlzPED] Immunization with a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer’s Disease- Associated Pathology in Transgenic Mice Patent Mucosal immunization to prevent prion infection Treatment of Alzheimer amyloid deposition
